You’ve been down this path before. You know how traditional CGM works, what the features and benefits are and the drawbacks you’ve experienced managing your diabetes. You’ve done self-insertions, over-taped sensors to stay on and needed to go through a warm-up period every 7-14 days with missed or inaccurate readings. With Eversense XL - the first and only long-term implantable CGM - you get to experience up to 180 days of Freedom!
Eversense XL CGM
No Sensor Self-Insertion
Eversense XL is inserted by your healthcare provider 2-3 times per year, letting you avoid the burdensome self-insertion process every 10-14 days.
Alarm Fatigued? Customize alerts to you!
Eversense XL can send you alerts customized to you – either receive pop-up messages on your phone, hear an alert or feel vibrations to alert you to highs and lows, based on your customized settings.
No Extra Receiver
With Eversense XL, you can see your readings directly on your compatible mobile device. And with readings every 5 minutes, you can see where you are now and where you’re headed with the trend arrows.1
Discreet and Flexible
The only CGM that offers you the flexibility and discretion to remove the transmitter without wasting a sensor.
Eversense CGM users report improved confidence and safety
Having diabetes is hard enough. Eversense wants to help make it easier for you to manage your diabetes. As part of our European clinical trial, we asked users how Eversense impacted their life.
CGM systems can help lower HbA1C1 and improve glycemic management,2 but
only a fraction of insulin-dependent people use them. Our solution aims to
fit CGM into your lifestyle, balancing performance and safety.
- Freedom from weekly sensor insertions for up to 180 days
- Eliminates site maintenance and management of supplies and reordering
- Eliminates discomfort and skin irritation associated with acrylate adhesives
Improved Glycemic Awareness
- On-body vibration alerts
- 90% of hypoglycemic excursions detected (70mg/dl)4
- 98% of hyperglycemic excursions detected (180mg/ml)4
- High accuracy over the 180 days of sensor life (MARD 9.4%)6
Ease of Use
- Up to 180 days of continuous glucose readings
- Professional insertion - no self-insertions
- A lifestyle friendly design - great for sports or just normal life events
- Removable and replaceable transmitter
Switch from traditional CGM and start your Eversense XL journey today!
Our Evesense XL CGM technology is engineered to take much of the time, hassle and discomfort out of the way, while giving you the info you need to help better manage your diabetes.
1 The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med 2008; 359:1464-1476 October. 2008. 2 Beck RW, MD, Hirsch IB, La_el L, Tamborlane WV, et al. E_ect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383. 3 De Bock M, Cooper M, Retterath A, et al. Continuous Glucose Monitoring Adherence: Lessons From a Clinical Trial to Predict Outpatient Behavior. Journal of Diabetes Science and Technology. 2016;10(3): 627-632.doi:10.1177/1932296816633484.2 4 Data on file. Senseonics 2018. 5 Summary of Safety and E_ectiveness Data (SSED) Medical Device Databases – http://www.fda.gov 6 Christiansen MP, Kla LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 7 Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, et al. E_ectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med. 2010;363:311-320. 8 Varma N, Michalski J, Stambler B, Pavri BB, TRUST Investigators. Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-up in the TRUST trial - testing execution of the recommendations. European Heart Journal. 2014;35(20):1345-1352. doi:10.1093/eurheartj/ehu066.